Nonphysiological truncations of apolipoprotein (apo) B-100 cause familial hypobetalipoproteinemia (FHBL) in humans and mice. An elucidation of the mechanisms underlying the FHBL phenotypes may provide valuable information on the metabolism of apo B-containing lipoproteins and the structure-function relationship of apo B. To generate a faithful mouse model of human FHBL, a subtle mutation was introduced into the mouse apo B gene by targeting embryonic stem cells using homologous recombination followed by removal of the selection marker gene by Cre-loxP-mediated site-specific recombination. The engineered mice bear a premature stop codon at residue 1767 and a 42-base pair loxP inserted into intron 24 of the apo B gene, thus closely resembling the apo B-38.9-producing mutation in humans. Apo B-38.9 was the sole apo B protein in homozygote (apob 38.9/38.9 ) plasma. In heterozygotes (apob ؉/38.9 ), apo B-100 and apo B-48 were reduced by 75 and 40%, respectively, and apo B-38.9 represented 20% of total circulating apo B. Hepatic apo B-38.9 mRNA levels were reduced by 40%. In cultured apob ؉/38.9 hepatocytes, apo B-100 was produced in trace quantities, and the synthesis rate of apo B-38.9 relative to apo B-48 was reduced by 40%. However, almost equimolar amounts of apo B-38.9 and apo B-48 were secreted into the media. Pulse-chase studies revealed that apo B-38.9 was secreted at a faster rate and more efficiently than apoB-48. Nevertheless, both apob ؉/38.9 and apob 38.9/38.9 mice had reduced hepatic triglyceride secretion rates and fatty livers. Thus, low mRNA levels or defective secretion of apo B-38.9 may not be responsible for the FHBL phenotypes caused by the apo B-38.9 mutation. Rather, a reduced capacity of apo B-38.9 for triglyceride transport may account for the fatty livers in these mice.
1 is the major structural protein component of the triglyceride-rich very low density lipoproteins (VLDLs) secreted from the liver and the chylomicrons secreted from the intestine. The full-length apo B (apo B-100) is composed of 4536 amino acid residues (1) . Due to a posttranscriptional modification of the apo B gene (apob) mRNA that converts codon 2153, CAA, to a stop codon, UAA, the apo B protein also naturally exists in a truncated form corresponding to the NH 2 -terminal 48% of apo B-100, designated apo B-48 (2, 3) . In humans, apo B-48 is produced only by the intestine, whereas both the intestine and the liver in rodents secrete apo B-48 (4, 5) . High levels of plasma apo B-containing lipoproteins are a major risk for the development of atherosclerotic diseases. Therefore, mechanisms controlling apo B synthesis and secretion are under active investigation.
Nonsense and frameshift mutations in apob that produce nonphysiological COOH-terminal truncations of apo B-100 cause familial hypobetalipoproteinemia (FHBL) in humans, an autosomal codominant disorder characterized by low levels (Ͻ5th percentile) of plasma apo B and low density lipoprotein (LDL) cholesterol (6, 7) . Numerous forms of truncated apo B, with sizes ranging from apo B-2 to apo B-89, have been identified in FHBL subjects (6, 8) , and they are usually present in plasma at much lower concentrations than apo B-100 due to low production and high fractional catabolic rates (6, 9 -11) . The molecular mechanism(s) underlying these metabolic alterations is yet to be elucidated.
In addition to the abnormalities in plasma cholesterol and apo B levels, fatty livers also occur in heterozygous FHBL subjects (12) (13) (14) (15) . Truncation-producing mutations in apob might impair the ability of the liver to secrete triglycerides due to low synthesis rates of the truncated apo B, its enhanced intracellular degradation, or its impaired assembly with lipids, resulting in a reduced capacity of the mutant apo B for transporting triglycerides. Gaining insights into apo B and lipid metabolism in FHBL at the molecular and cellular level may provide information critical not only to the elucidation of mechanisms for this disorder but also to defining further the structure-function relationship of apo B-100.
However, FHBL patients are usually asymptomatic (6, 7), posing ethical barriers to obtaining liver and intestinal biopsies for in-depth studies. In recent years, several lines of mice bearing various forms of apo B truncations have been generated by targeting apob in embryonic stem (ES) cells (16 -19) . In these mice, the targeted apob alleles were expressed at low levels, leading to very low concentrations of truncated apo Bs in the plasma (16 -19) . It is not known whether these low ob-served levels of mRNA expression faithfully represent the mechanisms of FHBL existing in humans because in the mice, multiple copies of the gene-targeting construct were inserted into apob along with the desired mutations (16 -19) . The presence of these foreign DNA sequences in the genome might exert unnatural effects on the expression of the targeted gene or on genes nearby (20) . In the meantime, due to the low intracellular concentrations of the mutant apo Bs in the mouse livers, it has been difficult to study their posttranslational fates. Consequently, little is known about the cellular secretion and the function of the mutant apo Bs. Furthermore, the effect of modifying mouse apob on hepatic triglyceride secretion is yet to be explored.
To generate a faithful mouse model of FHBL, we have used ES cell homologous recombination technology to introduce an apo B-38.9-specifying single-nucleotide deletion into the exon 26 of mouse apob. The selection marker gene sequence that was introduced into intron 24 of apob during the homologous recombination step was subsequently deleted using the Cre-loxP system (20, 21) . Thus, the targeted apob allele of the resultant mice contains only a subtle mutation in the coding region plus a 34-base pair (bp) loxP sequence inserted into the middle of intron 24. This model more closely resembles the naturally occurring human apob mutations than the previously reported apob gene-targeted FHBL mouse models, in which large segments of extraneous DNA were retained. The apo B-38.9-bearing mice display fatty livers as well as FHBL phenotypes. We provide evidence suggesting that low mRNA levels or defective secretion of apo B-38.9 may not be responsible for the manifestation of these phenotypes. The apo B-38.9 truncation is secreted by hepatocytes more efficiently than apo B-48, but it has a reduced capacity for cellular triglyceride transport.
EXPERIMENTAL PROCEDURES
Preparation of Targeting Construct-To construct a sequence replacement gene-targeting vector, an 11.5-kb BglII-BglII genomic fragment spanning mouse apob intron 23 through the 5Ј-end of exon 27 was isolated from a BAC clone that contains a mouse apob insert derived from W-4 (129/SvJ) ES cell genomic DNA (clone 12339) (Genome System, St. Louis, MO). This genomic apob fragment was subcloned into a modified, HindIII-negative Sp72 plasmid (Promega, Madison, WI) at the BglII site (designated mB11.5K). Based on sequence analysis, deletion of nucleotide 5449 on mouse apo B cDNA is predicted to produce a premature stop codon at the same position (i.e. residue 1767) as that occurring in the apo B-38.9 mutation of human FHBL subjects (22) (Fig.  1A) . To generate this mutation, an 8-kb HindIII-HindIII fragment spanning the entire exon 26 (Fig. 1B) was excised from mB11.5K and subcloned into a pAlter-1 vector (Promega) at the HindIII site for site-directed mutagenesis. A 38-base oligomer was used as a mutagenic primer (5Ј-CTCAAAAATGGACAAGTTAACAGTGGAGACAAGTTC-3Ј) to delete nucleotide 5449 and to create a novel HpaI site. After mutagenesis, a 7-kb HindIII-XhoI fragment was excised from the mutant insert and subcloned into pSP-72 at HindIII and XhoI sites. In the meantime, the 5Ј-region of the 11.5-kb mouse apob BglII fragment was cut from mB11.5K using XhoI (one XhoI site is located in exon 25, whereas the other is in the polylinker of Sp-72 encompassing the 5Ј-BglII site of the insert) and subcloned into a HindIII-negative Sp 72 plasmid at XhoI. A loxP-PGK-Neo-loxP cassette (20, 21) was inserted into the resultant plasmid at HindIII site using a filling in/ligation strategy that abolished the HindIII site. Thereafter, the entire insert containing a loxP-PGK-Neo-loxP cassette was excised from the vector using XhoI and inserted into the Sp72 vector containing the mutated exon 26 fragment at XhoI site. The apo B-38.9-producing gene-targeting vector was obtained by digesting the resultant plasmid with HindIII and BglII. This construct contained the fragment of mouse apob spanning intron 23 through the 3Ј-end of exon 26 with a loxP-Neo gene cassette (1.7 kb) inserted in the middle of intron 24 (Fig. 1B) .
Generation of Mutant Mice Producing Apo B-38.9 Truncations-The 129/SvJ blastocyst-derived ES cells, RW4 cells (Dr. T. J. Ley, Washington University School of Medicine) were transfected with the gel-purified apo B-38.9 targeting construct, and G418-resistant clones were isolated as described (20) . Clones that had undergone homologous recombination were identified by Southern analysis of HpaI-digested genomic DNA using a 0.3-kb HindIII-HpaI genomic fragment (Fig. 1B) as an external probe. The fidelity of the targeted mutation was confirmed by sequence analysis.
To delete the PGK-neo cassette from the site of homologous recombination, homologous recombinant ES cells were stably transfected with a plasmid encoding the Cre recombinase and PGK-hygro as described (20, 21) ; hygromycin-resistant clones were screened for deletion of the PGK-neo marker by Southern analysis using a 0.5-kb HindIIIXhoI genomic fragment as a probe (internal probe; Fig. 1C ).
C57BL/6 blastocysts were microinjected with ES cells from two PGKneo marker-deleted, apob-targeted ES cell clones and implanted into pseudopregnant Swiss Webster foster females as described previously (20) to produce chimeric progeny. Male chimeras were bred with C57BL/6 females to generate heterozygous apo B-38.9-mice (apob ϩ/38.9 ). The apob ϩ/38.9 mice were intercrossed to create homozygotes (apob 38.9/38.9 ). They were also bred with apo B-48-only (apob
48/48
) mice (23) (The Jackson Laboratory, Bar Harbor, ME) to generate apob 48/38.9 mice.
All mice were weaned at 3 weeks of age, housed in a specific pathogen-free barrier facility with a 12-h light/dark cycle, and fed a regular mouse chow diet (Ralston Purina, St. Louis, MO). All mice used in this study were of a mixed genetic background with 50% C57BL/6 and 50% 129/SvJ.
Anti-mouse Apo B Polyclonal Antibodies-Rabbit anti-mouse apo B antisera were developed in our laboratory previously (24) . In addition, to produce polyclonal antibodies specific for the NH 2 -terminal region of mouse apo B, a glutathione S-transferase (GST) fusion protein containing amino acids 26 -289 of mouse apo B was generated using a pGEX-2T vector (Amersham Pharmacia Biotech) and used as an antigen to immunize two rabbits using a standard protocol.
Western Blot Detection of Apo B and Lipoprotein Fractionation-To perform Western blot analysis, mouse plasma (3 l/well) or hepatocyte lysates (250 g protein/well) were electrophoresed on 3-12% gradient SDS-PAGE gels under reducing conditions and electrotransferred onto Immobilon (Millipore Corp., Bedford, MA). Apo B protein bands were visualized using rabbit anti-mouse apo B antisera or the anti-GST-apo B fusion protein antiserum as primary antibodies and an ECL Western blot detection kit (Amersham Pharmacia Biotech). The ECL signals were quantified both by analyzing the density of the protein bands on Kodak XAR-5 film using Sigma gel computer software (SPPS Science Corp., Chicago, IL) and by direct measurement of the signal intensity using a Kodak image-analyzer system (Eastman Kodak Co.).
A fast performance liquid chromatography (FPLC) Superose column (24) was used to assess the distribution of lipids and apo B within the lipoprotein fractions of mouse plasma. The distribution of apo B in each lipoprotein fraction was determined by Western blot analysis.
RNA Analysis-Total RNA was isolated from mouse livers and small intestines by a single step isolation method using RNAZol TM B (TelTest, Inc., Friendswood, TX). A primer extension assay was used to determine the relative amounts of apob transcripts arising from different apob alleles. To produce cDNA templates for this assay, a one-step reverse transcription-polymerase chain reaction (RT-PCR) kit (Roche Molecular Biochemicals) was used to generate a 1.35-kb fragment of mouse apo B cDNA spanning the 3Ј region of exon 25 and the 5Ј region of exon 26 encompassing the apo B-38.9 mutation from liver or intestinal RNA. We used the upstream PCR primer 5Ј-ACAACTGGTCAGC-CTCCTACACTGG-3Ј and the downstream PCR primer 5Ј-GTTGGTC-AAATCTAGAGCACC-3Ј. The 1.35-kb RT-PCR products were gel-purified and used as templates for primer extension assay. A 32 P-labeled 29-base-oligo primer (5Ј-TCTCTCACTGGACTTCTTCTCAAAAATGG-3Ј) corresponding to sequence immediately upstream of the apo B-38.9 mutation site was annealed to the cDNA templates at 50°C for 30 min and extended with AMV-reverse transcriptase (Roche Molecular Biochemicals) in the presence of dideoxy-GTP at 37°C for 90 min. Because of a single-bp deletion and an A 3 G exchange mutation introduced into the apob 38.9 allele, extension of apob 38.9 cDNA yielded a 34-bp product, whereas the apob ϩ and apob 48 cDNA extension gave rise to a 42-bp product. The extension products were resolved in an 8% polyacrylamide gel containing 7.5 M urea. The gel was dried and subjected to autoradiography and PhosphorImager quantification (Image Quant version 3.2; Molecular Dynamics, Sunnyvale, CA). RNA samples from three mice for each genotype were analyzed, and the data are presented as mean Ϯ S.D.
Northern blot analysis was used to determine the size and the levels of apob transcripts in the livers of apo B-38.9-producing mice and their wild type littermates. Thirty micrograms of total RNA were electrophoresed on a 0.8% agarose-formaldehyde gel and transferred and immobilized onto a GeneScreen nylon membrane (NEN Life Science Products). A SacI-HpaI-digested fragment of mouse apob corresponding to the 3Ј-region of exon 26 was radiolabeled with [␣-32 P]dCTP using a random primer labeling kit (Roche Molecular Biochemicals) and used to probe apob transcripts. Northern hybridization was carried out using Rapid-hyb buffer according to the manufacturer's instructions (Amersham Pharmacia Biotech). The blots were also stripped and probed with a rat glyceraldehyde-3-phosphate dehydrogenase cDNA (Sigma). The hybridization signals were quantified by PhosphorImager (Molecular Dynamics, Sunnyvale, CA). The relative apo B mRNA levels are expressed as ratios of apoB mRNA/glyceraldehyde-3-phosphate dehydrogenase mRNA. Data are presented as mean Ϯ S.D (n ϭ 3 animals).
Preparation of Mouse Hepatocyte Cultures-To isolate mouse hepatocytes, the portal vein of each mouse (males, 10 -12 weeks old) was cannulated under anesthesia with Metophane and pentobarbitol, and the liver was perfused with oxygenated Ca 2ϩ -and Mg 2ϩ -free Hanks'-buffered saline solution for 5 min followed by perfusion of oxygenated Hanks'-buffered saline solution containing 0.05% collagenase (Type IV; Sigma) for 5-10 min. The perfusate was drained through an incision in the hepatic vein. After perfusion, the liver was removed and submerged into ice-cold DMEM, and the cells were released gently. The resultant cell suspension was then filtered through a nylon mesh and centrifuged at 50 ϫ g for 1 min. The cell pellets were resuspended in ice-cold DMEM and repelleted. After three wash cycles, cells were resuspended in DMEM containing 10% fetal bovine serum (FBS). Viability of the cells (ϳ80%) was determined by Trypan exclusion. Cells were plated onto six-well plates (0.7 ϫ 10 6 cells/well) or 100-mm dishes (8 ϫ 10 6 cells/ dish) coated with poly-D-lysine (Sigma) and incubated at 37°C under 5% CO 2 in 10% FBS/DMEM. After 1 h of attachment, the cell monolayers were washed twice and incubated in 10% FBS/DMEM until use. All experiments involving cultured hepatocytes were commenced 7-8 h after the cells were cultured.
Apo B Secretion from Cultured Hepatocytes-To assess the apo B secretion by the cultured hepatocytes, the cells cultured on 100-mm dishes were washed three times with phosphate-buffered saline and then once with DMEM. They were then cultured in 10 ml of serum-free DMEM for 3 h. The conditioned media were collected and concentrated using Centricon-30 (Amicon Inc., Beverly, CA), and the cells were washed twice with phosphate-buffered saline and harvested. Aliquots of the concentrated media and cell lysates were subjected to SDS-PAGE and Western blot analysis to determine the relative amounts of cellular and secreted apo B. The relative apo B contents were normalized by cellular protein contents. Three independent experiments were performed. The data are presented as mean Ϯ S.D.
Metabolic Labeling and Pulse-Chase Studies to Determine Apo B Synthesis and Secretion-Continuous labeling experiments were performed to determine the synthetic rates and secretion rates of wild type apo B and apo B-38.9 in hepatocytes from heterozygous mice. After the initial 7-h incubation period, cells on six-well plates were washed three times with phosphate-buffered saline and incubated in methionine (Met)-and cysteine (Cys)-free DMEM for 30 min to diminish the cellular pool of Met and Cys. After this incubation, the media were replaced with 1 ml of Met-and Cys-free DMEM containing 150 Ci of ]cysteine metabolic labeling solution, for the specified time periods. At the end of each incubation period, media were collected and spun to remove trace amounts of the cells, and the cell monolayers were lysed in an immunoprecipitation buffer (150 mM NaCl, 5 mM EDTA, 50 mM Tris, pH 7.4, 0.0625 M sucrose, 0.5% Triton X-100, and 0.5% sodium deoxycholate). Appropriate amounts of a mixture of protease inhibitors (Roche Molecular Biochemicals) were added to the media and cell lysates.
To determine the secretion efficiency of the newly synthesized apo B, cells were washed and labeled as described above for 30 min. The media were replaced with 1 ml of DMEM containing 10 mM Met and 3 mM Cys, and cells were cultured for the specified time periods. Cells and media were then processed as described above for continuous labeling experiments.
Immunoprecipitations were carried out to quantify the labeled apo B in the cell or the medium. For this purpose, 100 l of 5ϫ immunoprecipitation buffer were added to each tube containing the conditioned media. Media and cell lysates were incubated at 4°C with gentle rotation for 12 h and then centrifuged at 10,000 ϫ g for 5 min to remove any unsolubilized proteins or cell debris. The resultant media and cell lysates were incubated with rabbit anti-mouse apo B antisera for 6-h at 4°C, and the immunoreaction complex was precipitated with protein A-agarose (Life Technologies, Inc.). After being washed five times with 0.5ϫ immunoprecipitation buffer, the immunoprecipitates were dissolved in SDS-PAGE gel loading buffer and resolved on a 3-12% gradient gel under reducing conditions. The gels were dried, and the radioactivity associated with apo B bands was quantified using a PhosphorImager. Three independent experiments were carried out for these studies.
Determination of Triglyceride Secretion from Cultured HepatocytesAfter the initial culture period, cells on six-well plates were washed three times with phosphate-buffered saline and then incubated in 1 ml of DMEM containing 200 Ci of [2] [3] H]glycerol (20 Ci/mmol; American Radiolabeled Chemicals, Inc., St. Louis, MO) for the specified time periods. At the end of each incubation, media were collected and centrifuged to remove any detached cells. Cell monolayers were scraped and harvested. Lipid in the media and cells were extracted (25) and separated by TLC. The triglyceride spots were scraped off and counted for 3 H radioactivity. Triplicate incubations were performed for each time point.
Determination of in Vivo Secretion Rates-Hepatic production of VLDL-triglyceride was measured in littermates of apob ϩ/ϩ , apob ϩ/38.9
, and apob 38.9/38.9 mice (male, 14 weeks old) after intravenous injection of Triton WR 1339 (Sigma) as described (26) . Mice were fed a fat-free, high carbohydrate diet for 8 h prior to the experiments, and Triton WR 1339 in 100 l of saline (500 mg/kg of body weight) was injected into the mice under light anesthesia with Metophane. Tail vein blood samples were taken at the specified times after injection for triglyceride measurement.
Quantification of Liver Lipid Contents and Oil red O Staining of Liver Sections-Lipids
were extracted from liver tissues as described (25) . The dried lipid extracts were dissolved in 1% Triton X-100 in chloroform, dried under a stream of N 2 , and redissolved in H 2 O as described (27) for determination of triglycerides, total cholesterol, and phospholipids using enzymatic kits (WAKO Chemicals USA, Inc., Richmond, VA). The hepatic lipid concentrations were expressed as g of lipid/mg of protein.
Oil-red O staining of livers was performed on frozen liver sections (10 m in thickness). After being fixed in 40% formaldehyde, the sections were stained in 0.3% Oil red O in 60% isopropanol for 10 min, washed in tap water, and then counterstained in hematoxylin.
Miscellaneous Procedures-Plasma levels of cholesterol, triglycerides, and phospholipids were determined enzymatically (WAKO Chemicals USA, Inc.). Cellular protein contents were determined using a modified Lowry method (28). Student's t test and analysis of variance were performed to determine the levels of significance of differences.
RESULTS
Apo B-38.9-producing Mice-The apo B-38.9-producing mutation in humans is caused by a single base pair deletion at nucleotide 5449, leading to a frameshift and subsequently converting codon 1767 (Val) into a stop codon (22) . Deleting the nucleotide at the same position in mouse apob also converts codon 1767 into a stop codon (Fig. 1A) . A replacement type gene-targeting vector was used to introduce this mutation into mouse ES cell apob via homologous recombination, followed by removal of the marker gene from the targeted allele via CreloxP-mediated site-specific recombination (Fig. 1B) . After electroporation of the gene-targeting construct into ES cells, 120 colonies were picked and screened for homologous recombination events by Southern blot analysis with a 3Ј-flanking probe that is external to the targeting construct (Fig. 1B) . Two targeted clones were identified, expanded, and transfected with a PGK-hygro-Cre vector to express the Cre recombinase. Clones were screened for deletion of the marker gene using a Neo gene probe and a mouse apo B probe corresponding to exon 25 (internal probe, Fig. 1B) . Five PGK-neo-negative clones were identified, as indicated by the shift in the size of the HpaI-HpaI fragment hybridized to the internal probe on Southern analysis (4.7 kb with the Neo gene versus 3.0 kb without the Neo gene) and the lack of hybridization to the labeled Neo gene cDNA probe (not shown). High percentage male chimeras were bred with C57BL/6 females. The apob ϩ/38.9 offspring developed normally and were fertile. To avoid any potential confounding effect of expression of the Cre-transgene on lipoprotein metabolism, we used only Cre gene-negative offspring for further breeding. Typical Southern blot analysis and PCR analysis used to screen for mutant animals are shown in Fig. 1 , panels C, D, and E. Western analysis showed that the mouse and human apo B-38.9 are of very similar apparent molecular weights (Fig. 1, F and G) .
Intercrosses of apob ϩ/38.9 mice produced viable offspring apob 38.9/38.9 . The apob 38.9/38.9 mice were apparently healthy and fertile. However, the numbers of apob 38 48/38.9 mice. Rabbit antisera raised against a GST fusion protein containing amino acids 26 -289 of mouse apo B were used to determine the precise relative molar concentrations of plasma apo B-100, apo B-48, and apo-B38.9 in the mice. Because apo B-100, apo B-48, and apo B-38.9 all contained the entire apo B protein sequence included in this fusion protein, these antisera are expected to recognize epitopes common to these three different forms of apo B, thus providing accurate molar ratios for these apo Bs. On Western blotting, the anti-mouse apo B and the anti-fusion protein antibodies provided similar apo B protein ratios (data not shown), indicating that the anti-mouse apo B antiserum (R272) also recognized epitopes that are common to mouse apo B-100, apo B-48, and apo B-38.9. The relative concentrations of plasma apo B-100, apo B-48, and apo B-38.9 in various mice are shown in Fig. 2 . Apo B-38.9 accounted for 20 and 30% of the total plasma apo B molecules in apob ϩ/38.9 and apob 48/38.9 mice, respectively ( Fig. 2A) . Plasma levels of apo B proteins were reduced by 45 and 85% in apob ϩ/38.9 and apob 38.9/38.9 mice, respectively ( Fig. 2A) . As previously reported in other FHBL mouse models (16 -19) , a much greater decrease was seen in plasma levels of apo B-100 than those of apo B-48 (70% versus 40%) ( Fig. 2A) .
There were no significant differences in plasma concentrations of triglycerides, total cholesterol, and phospholipids between apob ϩ/ϩ mice and apob ϩ/38.9 , apob 48/48 , and apob 48/38.9 mice (Table I) . However, in the apob 38.9/38.9 mice, there were significant decreases in plasma levels of triglycerides, cholesterol, and phospholipids (Table I) . On FPLC analysis, cholesterol peaks corresponding to VLDL and LDL diminished in the plasmas of apob ϩ/38.9 and apob 38.9/38.9 mice (Fig. 3A) , whereas significant decreases in HDL cholesterol were observed only in the apob 38.9/38.9 plasma. Because VLDL and LDL cholesterol accounts for only a very small fraction of plasma cholesterol in mice, the reduction in VLDL and LDL cholesterol did not lead to a significant decrease in plasma cholesterol in the apob ϩ/38.9 mice. On Western blot analysis of the FPLC fractions of the apob ϩ/38.9 plasma, apo B-38.9 eluted with HDL-sized particles (fractions [25] [26] [27] [28] [29] [30] [31] [32] (Fig. 3B) .
Relative Levels of Apo B mRNA Expression by the Wild Type and Mutant Alleles-We examined the ratios of apob ϩ to apob 38.9 mRNA transcripts by a primer extension assay. Fragments of mouse apo B cDNA spanning exon 25 and the 5Ј- (22) is shown in boldface and indicated by an arrow, whereas the resultant premature stop codons (TAA) are boldface and underlined. Partial sequence of the mutagenic (mut.) primer used for site-directed mutagenesis to create this mutation in the mouse apob is also shown, and the mismatched nucleotides meant to create a novel HpaI site are underlined. B, gene targeting strategy. A sequence replacement-type gene targeting construct was prepared using a 11.5-kb BglII-BglII mouse apo B genomic fragment (intron 23 to exon 27) isolated from a BAC clone containing an RW-4 (129/SvJ) ES cell-derived apob insert as described under "Experimental Procedures." The targeting construct contained the fragment of mouse apob spanning exon 23 through the 3Ј-end of exon 26 with a loxP-PGK neo-loxP cassette (1.7 kb) inserted to intron 24 at HindIII by filling in-ligation, thereby abolishing the internal HindIII restriction site. A 0.3-kb mouse genomic fragment (HindIII-HpaI) corresponding to the 3Ј-end of apob exon 26 was used as an external probe for Southern analysis to screen for homologous recombinant ES cell clones. This probe hybridized to 9-and 6-kb HpaI-digested genomic fragments of the wild type and targeted apob alleles, respectively. Overexpression of Cre recombinase in the targeted ES cells induced deletion of the PGK neo-loxP sequence, leaving only subtle mutations in the targeted allele. An internal probe spanning the 3Ј-end of intron 24 and exon 25 (HindIII-XhoI) was used for Southern analysis to screen for PGK neo-loxP-deleted clones. C, a typical Southern blot showing hybridization of 32 P-labeled external probes to HpaI-digested genomic DNA from apob ϩ/ϩ , apob ϩ/38.9
, and apob 38.9/38.9 mice. D, Southern analysis confirming the absence of PGK-neo sequence in the apo B-38.9 carrying mice. DNA was digested with HpaI and 32 P-labeled internal probes were used for Southern analysis. The 9-kb bands represent the wild type alleles, and the 4.7-kb band represents the targeted allele before the PGK-neo sequence was deleted (ES cell clone 89). The reduction in the size of the targeted allele-band from 4.7 to 3 kb indicates the absence PGK-neo marker gene in the apob ϩ/38.9 mice. E, PCR and restriction-digestion analysis confirming apo B-38.9 mutation. A 296-kb fragment encompassing the apo B-38.9 mutation site was amplified and restriction-digested with HpaI. Lanes 1, 3, and 5, digestion with HpaI; lanes 2, 4, and 6, uncut controls. F and G, detection of apo B-38.9 by Western analysis. Two microliters of mouse (F) or human (G) plasma were separated on a 3-12% SDS-PAGE gel. Polyclonal rabbit anti-mouse apo B antisera were used for detection of mouse apo B, whereas a monoclonal anti-human apo B antibody (C1.4) was used for the human samples. Note that mouse apo B-38.9 and human apo B-38.9 are of nearly identical apparent molecular weights. region of exon 26 that included the apo B-38.9 mutation site (1.3 kb) were amplified from mouse liver and intestinal RNA by RT-PCR (Fig. 4A ) and used as templates for primer extension reactions. Extension of templates from the tissues of apob ϩ/38.9 mice yielded two bands, whereas templates from apob ϩ/ϩ or apob 38 .9/38.9 mice produced only single bands (Fig. 4B) . No extension of the labeled primer occurred when the RT step was omitted in the RT-PCR (Fig. 4B) , demonstrating the specificity of the assay. Levels of apob 38.9 transcripts were 62 Ϯ 3% of those of the apob ϩ allele in the livers and intestines of apo ϩ/38.9
(n ϭ 3) and apob 48/38.9 mice (n ϭ 3). On Northern blot analysis, there were no differences in the sizes of apob ϩ and apob 38.9 transcripts (Fig. 5B) . Compared with apo B wild type littermates, apo B mRNA levels in the liver of apob ϩ/38.9 and apob 48/38.9 mice were reduced by approximately 22% (Fig. 5A) , whereas those of the apob 38.9/38.9 mice were reduced by 47%, confirming the results obtained from the primer extension assay (Fig. 4) . The decrease in apob 38.9 mRNA levels fully accounted for the difference in total apo B mRNA levels between the apob ϩ/ϩ and apob ϩ/38.9 mice, indicating that apo B-38.9 mutation does not affect the mRNA expression of the wild type allele.
Synthesis and Secretion of Apo B-48 and Apo B-38.9 by Cultured Hepatocytes-Next, we determined in cultured hepatocytes the intracellular contents of apo B and the amounts of apo B secreted into the cultured media using Western blot analysis. In the apob ϩ/ϩ hepatocytes, apo B-100 and apo B-48 accounted for 5 and 95% of the total cellular apo B, respectively (Fig. 6A) . In the apob ϩ/38.9 cells, apo B-48 levels were reduced by 50% compared with the apob ϩ/ϩ cells (Fig. 6A) . Furthermore, the intensity of the apo B-38.9 band was approximately 53% of that of the apo B-48 in the apob ϩ/38.9 cells, whereas apo B-100 was barely detectable (Fig. 6A) . In apob 38.9/38.9 cells, apo B-38.9 was present at levels approximately 50% of those of apo B-48 in apob ϩ/ϩ cells (Fig. 6A) . After a 3 h-incubation period in DMEM, conditioned media from the apob ϩ/38.9 hepatocytes contained 50% less apo B-48 than the media from the apob ϩ/ϩ cells (Fig. 6B) . Apo B-100 bands in media were visible only after a prolonged exposure time (not shown). Unexpectedly, equal amounts of apo B-48 and apo B-38.9 accumulated in media of apob ϩ/38.9 hepatocytes (Fig. 6B) , indicating that apob ϩ/ϩ and apob ϩ/38.9 cells may have secreted nearly equimolar amounts of apo-48 and apoB-48 plus apoB-38.9, respectively. Indeed, despite the 2-fold difference in the cellular apo B contents of apob ϩ/ϩ and apob 38.9/38.9 cells, equal molar amounts of apo B were secreted into the media (Fig. 6B) .
During a continuous labeling period of 3 h, there were 1.6 -2 times as much labeled apo B-48 as apo B-38.9 in the apob ϩ/38.9 cells (Fig. 7A) , but similar amounts of 35 S-labeled apo B-48 and apo B-38.9 were secreted into the media (Fig. 7B) , confirming the mass measurements (Fig. 6B) . The total amounts of labeled mice (P Ͻ 0.01, n ϭ 6).
FIG. 2.
Effects of the apo B-38.9-producing mutation on plasma apo B levels. Plasma samples were obtained from mice after a 4-h fast and subjected to SDS-PAGE (3-12% gel) (2 l/well). Rabbit antisera raised against a GST-mouse apo B (amino acids 26 -289) fusion protein were used as primary antibodies for Western analysis using an ECL kit. The ECL signals were quantified as described under "Experimental apo B-48 and apo B-38.9 (i.e. secreted plus cellular) increased linearly within the 3 h-incubation period (Fig. 7C) . Signals for the apo B-100 bands were barely detectable (data not shown). Pulse-chase experiments were then performed to determine the secretion efficiency of the newly synthesized apo B-48 and apo B-38.9 from the apob ϩ/38.9 hepatocytes. Again, equal amounts of the labeled apo B-48 and apo B-38.9 were secreted into the media at the indicated chase time points despite the fact that cells synthesized less apo B-38.9 than apo B-48. (Fig.  8, A and B) . At the end of the chase period, approximately 27 and 40% of the initially labeled apo B-48 and apo B-38.9, respectively, were secreted into the media (Fig. 8B) . Apo B-38.9 also appeared to be secreted at a faster rate than apo B-48 (Fig.  8B) . Thus, both metabolic labeling experiments confirmed the results of mass measurements that the apo B-38.9 mutation does not reduce the secretion rates of the resultant truncated apo B relative to apoB-48 from the same cells.
All of the above experiments were also performed with apob 48/38.9 hepatocytes. The results were very similar to those of the apob ϩ/38.9 cells (data not shown). Effects of Apo B-38.9 Mutation on Hepatic Triglyceride Secretion-The secretion rates of newly synthesized triglycerides decreased by 40% in the hepatocytes of apob ϩ/38.9 mice and by 70% in hepatocytes of apob 38.9/38.9 mice relative to the apob ϩ/ϩ cells, whereas more newly synthesized triglycerides were accumulated by the apob ϩ/38.9 and apob 38.9/38.9 cells than by the apob ϩ/ϩ cells (Fig. 9 ). Likewise, in vivo studies using Triton WR-1339 to block plasma triglyceride clearance showed that triglyceride secretion rates were decreased by 30 and 70% in the heterozygotes and homozygotes, respectively (Fig. 10) .
Fatty Livers Resulting from Apo B-38.9 Mutation-Hepatic triglyceride contents were increased 2.3-and 5-fold in the heterozygotes and homozygotes, respectively (Fig. 11) . No significant changes occurred in hepatic phospholipids and total cholesterol contents (Fig. 11) . Oil red O staining of frozen liver sections confirmed the quantitative analysis (Fig. 12) . Differences in the sizes of intracellular lipid droplets were also readily detected in freshly isolated hepatocytes under the light contrast microscope (Fig. 12, insets) .
DISCUSSION
The FHBL associated with apo B-truncation-producing mutations is the best characterized subset of FHBL (6, 7). However, although the molecular bases of the genetic defects have been established, the corresponding cellular and molecular mechanisms that produce the FHBL phenotypes are relatively poorly understood. Previous studies using apob-modified mice suggested that reduced mRNA levels of the mutant apob allele and the presumed resulting low production rates of apo Bcontaining lipoproteins might be primarily responsible for the FHBL phenotypes (16 -19) . In the current study, we have utilized a novel gene-targeting strategy to generate a mouse model that closely resembles the natural apo B-38.9 mutation in humans. In this FHBL model, levels of the apob 38.9 mRNA expression and intrahepatocytic synthetic rates of apo B-38.9 were reduced by approximately 40%. However, we did not note corresponding decreases in the rates of apo B-38.9 secretion. In fact, apo B-38.9 was secreted more efficiently than apo B-48. Thus, we demonstrated a dissociation between low apo B-38.9 mRNA levels and low apo B-38.9 synthesis rates on the one hand and the high secretion efficiency of apo B-38.9 on the other. Despite efficient apo B-38.9 secretion, rates of hepatic triglyceride secretion were reduced. This indicates that apo B-38.9 is defective for triglyceride transport, resulting in development of fatty livers in the mice. These are new insights FIG. 4 . Allele-specific analysis of relative levels apo B mRNA expression using a primer extension assay. A, generation of cDNA templates by RT-PCR. Mouse apo B cDNA fragments corresponding to a region including exon 25 and the 5Ј-end of exon 26 were amplified from liver (Liv.) and intestinal (Intest.) RNA. The specific PCR products (indicated by an arrow) were gel-purified and used for primer extension assay. B, primer extension of apo B cDNA templates. Extension of apob 38.9 cDNA templates yielded a 34-bp product, whereas the apob ϩ and apob 48 cDNA extension gave rise to a 42-bp product. The bands were quantified using a PhosphorImager. into the structure-function relationship of apo B, as well as the FHBL syndrome. The apo B-38.9 mouse model reported here is unique in that only a single base pair deletion (nucleotide 5449) was introduced into the mouse apob coding region and one copy of Lox-P sequence (43 bp) was inserted into the middle of intron 24. Therefore, unlike the complex alterations introduced into apob in the previously reported FHBL mice (16 -19) , the apob modifications occurring in our mouse model are relatively minor and are very close to replicating a natural apo B-truncationproducing mutation in humans. The apo B-38.9-bearing mice displayed characteristics typical of FHBL in humans, including low plasma levels of apo B-100 and apo B-38.9 and LDL cholesterol. Plasma levels of HDL cholesterol were dramatically reduced in the homozygous mice. Similar observations have been made in prenatal mice homozygous for apob null-knockout (29) , adult mice homozygous for the apo B-70-truncation (16) , and mice bearing a liver-specific knockout of the microsomal triglyceride transport protein large subunit gene (30, 31) . The decreased HDL levels in these mice appeared to be mainly due to enhanced HDL catabolism because apo AI synthesis was not affected (16, 29) . We also observed no significant changes in the liver contents of apo AI protein and apo AI secretion by the hepatocytes due to the apo B-38.9 mutation (data not shown). Viable apob 38.9/38.9 mice were born and reached adulthood in significant numbers, albeit fewer were born than expected. Apo B plays an essential role in yolk sac nutrient transport for normal mouse embryonic development (29, 32) . The ability of apob 38.9/38.9 mice to survive indicates that apo B-38.9 may be capable of performing this transporting role, at least in part.
One of the major issues we wanted to clarify was whether and to what extent the apo B-38.9-specifying mutation affects the steady-state level of apoB mRNA, given the previously reported low apoB mRNA levels (ϳ 10 -30% of normal) in the , and apob 38.9/38.9 hepatocytes. Hepatocytes were isolated and cultured for 7 h in 10% FBS/DMEM. Thereafter, the cell monolayers were washed and cultured for 3 h in serum-free DMEM. Relative apo B levels in the cells and in the conditioned media were determined by Western analysis using rabbit anti-GST-apo B (amino acids 26 -289) antisera. Each column represents the mean Ϯ S.D. of the numbers of independent experiments (n ϭ 4 for apob ϩ/ϩ and apob ϩ/38.9 ; n ϭ 2 for apob 38.9/38.9 S-Promix for 0, 45, 90, and 180 min in Met-and Cys-free DMEM. Apo B proteins in the cell lysate or the medium were immunoprecipitated and resolved on SDS-PAGE (3-12% gel) and quantified using a PhosphorImager, and the intensities of the signal were expressed as arbitrary units. Similar results were obtained from two additional experiments. Signals for apo B-100 were barely detectable and are not shown in the figure. apoB truncation-bearing mice (16, 18, 19) . On allele-specific mRNA analysis and Northern blotting, the apo B-38.9 mutation did not affect the levels of mRNA expression of the wild type allele in heterozygotes, but it decreased the levels of mRNA expression of the apob 38.9 allele by 40 -50%. The magnitude of this decrease is much smaller than those reported in other genetically engineered FHBL mice (16, 18, 19) , including the apo B-39-producing mice, which bear an apob premature stop codon only 18 residues downstream from the apo B-38.9-COOH terminus (19) . The mutant apob 81 allele was expressed at an even lower level than the apob 39 allele (19) although the apo B-81-and apo B-39-bearing mice were produced using an identical gene-targeting strategy (18, 19) . In contrast with premature stop codons in the nonphysiological apo B-truncation sites, placing a nonsense mutation by in/out gene targeting at the apo B-editing site (apo B-48) had no effect on apo B mRNA (23) . In fact, premature stop codons can be associated with either low (33) (34) (35) or unaltered (36 -38) mRNA expression for different genes. Thus, it is not clear whether the differences in mutant apob mRNA levels between the various mice are related to the different gene-targeting strategies used, to the specific location of the premature stop codon, or to the length of the open reading frame on the apob transcript.
Apo B-48 synthesis and secretion were reduced by 50%, as expected, in apob ϩ/38.9 hepatocytes compared with apob ϩ/ϩ hepatocytes, indicating that the apo B-38.9 mutation does not interfere with the production rates of apo B-48 from the normal allele. A surprising finding is that although the apo B-38.9 mutation decreased apob 38.9 mRNA levels and the rates of intrahepatocytic apo B-38.9 synthesis by 40 -50%, it did not cause a corresponding decrease in the cellular secretion of apo B-38.9 because apo B-38.9 was secreted more efficiently than apoB-48 by hepatocytes. In fact, nearly equal molar amounts of total apo B were secreted by the apob ϩ/ϩ , apob ϩ/38.9 , and apob 38.9/38.9 hepatocytes. Previous studies (39, 40) using rat hepatoma cells overexpressing truncated apo B proteins have suggested that COOH-terminal truncation of apo B-100 does not impair the secretion of the resultant truncated apo B. The present study, for the first time, provides data verifying these observations under physiological settings. Unlike the situation in human livers, in which the apo B-100 is the sole apob product, apo B-48 accounted for more than 95% of the wild type apoB allele product from hepatocytes of the apob ϩ/ϩ and apob ϩ/38.9 mice, consistent with previous observations (5, 30, 41) . The relative rates of secretion of apoB-100 and apoB 38.9 remain to be determined in apob 100/38.9 mice. Triglyceride secretion was decreased in the hepatocytes of apob ϩ/38.9 mice and severely impaired in apob 38.9/38.9 mice, indicating that apo B-38.9, although secreted in expected molar quantities, may not be as capable as apo B-48, the physiological form of truncated apo B, for transporting triglycerides. This finding is consistent with a recent study of apo B-39-bearing mice that showed that the particle volume of plasma apo B-39-VLDL was only about half that of the apo B-48-VLDL (19) and with studies of rat hepatoma cells transfected with truncated human apo B cDNAs that demonstrated that the length of the apo B truncation is positively correlated with the size but 
FIG. 12.
Oil red O staining of frozen liver sections from apob ϩ/ϩ , apob ϩ/38.9 , and apob 38.9/38.9 mice. Oil red O staining was performed as described under "Experimental Procedures." Insets show the presence of large lipid droplets in the hepatocytes of apob 38.9/38.9 mice under a light contrast microscope.
Apo B Secretion and Fatty Livers in Apo B-38.9-bearing Mice
inversely correlated with the buoyant density of the truncated apo B-containing lipoprotein particle (42) . Compatible observations have been made on apo B-containing lipoproteins in human FHBL subjects (6, 22, 43) ; e.g. human kinetic studies have shown that the majority of apo B-43.7-containing lipoproteins enter the plasma as HDLs (43) .
Several cases of fatty livers have been reported in heterozygous FHBL human subjects (12) (13) (14) (15) . A previous study has shown that truncating apo B at residue 1768 (i.e. apo B-38.95), only one residue downstream from the apo B-38.9-COOH terminus, caused fatty liver in a heterozygous FHBL patient (12) . Furthermore, we have recently demonstrated that human subjects heterozygous for apo B-4 or apo B-9 truncations have reduced hepatic VLDL-triglyceride secretion rates (44) . The results of the present study confirm and greatly extend the findings in humans. Thus, selected mutations in the apo B gene could cause a subset of fatty livers.
Although apo B-48 and apo B-38.9 were secreted at similar rates in apob ϩ/38.9 mice, the plasma concentration of apo B-38.9 was only about half of that of apo B-48. Likewise, the apo B-38.9 levels in plasmas of heterozygous FHBL human subjects were much lower than those of apo B100 (22) . Most of the human (22) and mouse apo B-38.9 particles are of HDL particle sizes, whereas the apo B-48 particles are much larger. Due to their smaller sizes, the Lp B-38.9 particles may be distributed in the interstitial fluid, as well as in plasma, thereby diluting the plasma pool of apo B-38.9. Furthermore, apo B-38.9 may be cleared from plasma at a faster rate than apo B-48. We have previously shown that human lipoproteins containing short apo B truncations, including apo B-38.9, were cleared from the plasma much more rapidly than the apo B-100-LDL particles (45) . We subsequently identified a renal proximal tubular endocytic receptor, megalin, as the key receptor involved in catabolism of apo B-70.5-containing lipoproteins (46) . The megalin binding site of apo B appears to be in the NH 2 -terminal region within apo B-31 (47) . Thus, megalin may also play an important role in rapid clearance of apo B-38.9 particles from the plasma.
In conclusion, the results of this study strongly suggest that low levels of mRNA expression or a defective secretion of apo B-38.9 may not be responsible for manifestation of the FHBL phenotypes and fatty livers in our apo B-38.9-bearing mice. Rather, our study implies that positioning a premature stop codon 386 residues upstream from the apo B-48-COOH terminus in a mouse results in an apo B-38.9 with an enhanced hepatic secretion efficiency but decreased triglyceride transporting capacity and fatty livers.
